On January 22, GlaxoSmithKline (GSK) announced that its holding joint venture, ViiV Healthcare1, is a single-chip compound based on the new generation of integrase inhibitor Tweekai (chemical name: doneiravir) for the treatment of HIV. The preparation of 绥美凯 (chemical name: Dotti Apalami tablets) was officially listed in mainland China. This is the first complete combination of the first complete treatment regimen in the field of HIV treatment in mainland China. The retail price is 2880 yuan / month, lower than the surrounding countries and regions.
英文美凯 English name is Triiumeq, the ingredients are dolategravir 50mg (dolutegravir) + abacavir 0.6g (abacavir) + lamivudine 0.3g (lamivudine) three drugs for HIV-1 infection The treatment is the only three-in-one combination drug containing dobutavir, once a day, once a piece, with high efficiency, tolerance, high resistance barrier, and low drug interaction.
绥美凯 first listed in the US in 2014. After the product went on the market, the market sales increased rapidly, reaching US$2.2 billion in 2016. In 2015, Glaxo submitted a clinical application in China, applied for import on January 20, 2017, and obtained the priority review qualification. On August 1, 2017, it was approved by the CFDA. At present, 绥美凯 has been approved for marketing in 50 countries and regions, and has been recommended by many academic institutions and guidelines in Europe and the United States as the first-line treatment for treatment of HIV-infected patients.
Following the launch of the new HIV treatment drug Tweed in 2016, this is another new drug for GSK that has been approved for marketing in mainland China. Shuangzhizhi is GSK's first approved HIV antiviral treatment in China.
According to public data, as of the end of October 2017, China reported a total of 746,000 HIV-infected and AIDS patients, with a reported death of 229,000. The number of people receiving antiretroviral treatment at the end of 2016 was 495,000.
Zhang Fuji, director of the Center for Infection and Clinical Research at Beijing Ditan Hospital, Capital Medical University, said: "At present, global antiviral treatment is gradually entering the era of integrase inhibitors, and fixed-dose combination preparations have become the trend of future treatment. Integrase inhibitors have stronger The four main features of antiviral action, less toxic side effects, less drug interactions, and less resistance to drug resistance. Indigo is a single-chip combination drug containing a new generation of integrase inhibitor DTG. A more convenient and efficient combination of integrase inhibitors for HIV-infected people in China is a major advancement in existing antiviral treatment in China."
Wei Liansheng, General Manager of GSK China's Prescription Drugs and Vaccines Department, said: “We are offering another innovative treatment for HIV-infected people. We are working with a number of organizations to develop HIV/AIDS care professionals, disease prevention and education. Projects to enable HIV-infected people to get better support and help."
Anchovy Fish
Anchovy Fish,Frozen Anchovies,Raw Anchovies,Flat Anchovies
ZHEJIANG EVERNEW SEAFOOD CO.,LTD , https://www.evernewseafood.com